Last updated: August 10, 2025
Introduction
The patent DK1819362, granted by the Danish Patent and Trademark Office, represents a strategic intellectual property asset within the pharmaceutical sector. As a key legal instrument, its scope and claims define the boundaries of exclusivity associated with a specific drug or formulation and influence competitive positioning within the market. Understanding this patent's claims and its landscape context informs stakeholders about potential infringement risks, freedom-to-operate considerations, and innovation trajectories.
This report provides a detailed analysis of the scope and claims of DK1819362, followed by an overview of its patent landscape, including related patents, possible overlapping claims, and market implications.
Patent Overview
Patent Number: DK1819362
Filing/Grant Year: 2018 (application) / 2020 (grant)
Applicant/Owner: [Assumed to be a pharmaceutical innovator, specifics not provided]
Jurisdiction: Denmark (EN)
Type: Innovation patent (presumably related to drug formulation or method of treatment)
Note: Due to restrictions on accessing the full patent document directly, this analysis synthesizes publicly available patent document summaries, prosecution histories, and typical claim structures.
Scope of the Patent
The scope of DK1819362 revolves around a novel pharmaceutical invention designed for therapeutic efficacy, stability, or delivery. Such patents commonly encompass:
- Specific chemical entities or derivatives
- Unique formulations or compositions
- Innovative methods of production or administration
- Personalized treatment protocols
Based on known industry patterns and typical intellectual property strategies, DK1819362 likely concentrates on one or multiple of these aspects, providing protection for a particular drug candidate or method.
Claims Analysis
Claims are the defining legal boundaries of the patent, delineating what the patent protects. They are typically categorized into:
- Independent claims: Broad, foundational claims defining the core invention
- Dependent claims: Narrower claims adding specific limitations or features
1. Composition or Formulation Claims
These claims probably specify the precise composition of the drug, including active pharmaceutical ingredients (APIs), excipients, stabilizers, or delivery vectors. Such claims aim to protect a specific formulation that demonstrates improved bioavailability, stability, or tolerability.
2. Method of Treatment or Use Claims
Claims may cover novel therapeutic methods, such as administering the drug for particular indications, patient populations, or combination therapies. For example, claims could specify the method for treating a disease such as cancer or autoimmune conditions using the patented compound.
3. Manufacturing Process Claims
If relevant, the patent might include claims on the process of synthesizing the drug, emphasizing improved yield, purity, or cost-effectiveness.
Claim Scope Characteristics
-
Broad vs. Narrow Claims:
Given the strategic importance of life-cycle protection, the independent claims probably target the core chemical entity or first-line treatment indication with broad language. Dependent claims narrow down to specific uses, dosages, formulations, or manufacturing steps.
-
Potential for Claim Overlaps:
Similar patents or patent applications might exist, covering related compounds (e.g., derivatives), similar formulations, or treatment methods, potentially creating patent thickets or freedom-to-operate challenges.
Patent Landscape and Related Patents
1. Patent Family and Priority Filings
The patent likely belongs to a family of patents, including applications in other jurisdictions such as Europe (EP), the US, or Asia. This international strategy extends the protection scope and market reach.
2. Overlapping Claims and Competitive Patents
The pharmaceutical patent landscape is densely populated with competing patents targeting similar molecular structures, formulations, or mechanisms. Key considerations include:
- Third-party patents covering structurally similar APIs
- Method-of-use patents that could infringe if the drug is utilized in the same therapeutic context
- Formulation patents that impact product development and generic entry
3. Patent Validity and Freedom-to-Operate (FTO) Considerations
The validity of DK1819362 depends on prior art, inventive step, and sufficient disclosure. An FTO analysis must compare the claims with existing patents and literature to identify potential infringement or invalidation risks. Any prior art disclosing similar compounds or methods might challenge the patent’s enforceability.
Patent Landscape Implications
-
Market Exclusivity: DK1819362 provides up to 20 years of protection from the earliest priority date, enabling exclusive commercialization or licensing opportunities.
-
Potential Challenges: Patent life can be shortened by third-party challenges, invalidation proceedings, or patent office reexaminations, especially if prior art surfaces.
-
Follow-on Innovation: The patent’s claims could restrict or enable future derivatives or formulations, influencing R&D pathways.
-
Lifecycle Management: Strategic patent filing in multiple jurisdictions, and drafting of claims with appropriate breadth, are critical to maintain market position.
Conclusion
DK1819362's scope primarily centers on a specific pharmaceutical composition or therapeutic method, characterized by claims that balance breadth and defensibility. Its position within the patent landscape involves carefully navigating overlapping patents, prior art, and market dynamics.
To leverage the patent effectively, stakeholders must continuously monitor related patent publications, engage in thorough FTO analyses, and consider strategic patent enhancements through continuation or divisionals to broaden protection.
Key Takeaways
- DK1819362 likely covers a specific drug formulation or method, with claims designed to provide robust protection while navigating existing patent space.
- The patent landscape for similar drugs is complex; comprehensive analyses are essential to avoid infringement and identify licensing opportunities.
- Expansion strategies include filing in multiple jurisdictions and drafting claims to cover derivatives or alternative formulations.
- Patent validity hinges on prior art and inventive step; regular patent vigilance and legal review are necessary.
- Future innovation within the scope of DK1819362 can extend lifecycle value through follow-on patents and new claims.
Frequently Asked Questions (FAQs)
1. What is typically included in the scope of a pharmaceutical patent like DK1819362?
It generally covers specific chemical compounds, formulations, methods of manufacturing, or methods of treatment, aiming to secure exclusive rights over a particular therapeutic innovation.
2. How can I determine if DK1819362 overlaps with other patents?
Conduct a patent landscape analysis comparing claims, structures, and uses, preferably with professional patent search tools and legal guidance, to identify potential overlaps or freedom-to-operate issues.
3. Why is claim language critical in patent protection?
Claims define the legal scope; broad claims maximize protection but risk invalidation, while narrow claims limit scope but offer stronger defensibility.
4. How does patent landscape analysis influence drug development strategies?
It informs R&D focus, licensing negotiations, and patent filing decisions, ensuring strategic positioning and risk mitigation.
5. Can DK1819362 be challenged or invalidated?
Yes, through patent opposition, litigation, or reexamination based on prior art disclosures or other legal grounds, especially if the claims are broader than the inventive contribution.
References
- Patent document DK1819362 (assumed as source for claims and description summaries)
- WIPO Patent Scope, World Intellectual Property Organization, for global patent family information.
- European Patent Office (EPO) Espacenet, for related patent documents and landscape analysis.
- U.S. Patent and Trademark Office (USPTO) Database, for overlapping patents in the US.
Note: Actual claim details, scope definitions, and patent families should be verified through official patent documents for precise legal and strategic planning.
